Zum Tag der Deutschen Einheit ein Rückwurf: So reagierten die Grünen damals. Linke hassen Deutschland und die Deutschen. Schon immer. Zitat: „Überflüssig und gefährlich hingegen bleibe ‚die Vision eines Wirtschafts- und Machtmonopols von 80 Millionen Deutschen‘.“
Sven Hüber ist der Polizeigewerkschafter und Vertraute von Nancy Faeser, welcher kürzlich Polizeibeamte zum Widerstand gegen eine potentielle AfD-Regierung aufgerufen hat.
„EXKLUSIV: Sven Hüber setzte laut Zeugenaussage an der Berliner Mauer aus Überzeugung und mit Willen zur „Vernichtung“ den Schießbefehl durch.
Der hochrangige Polizeigewerkschafter, der Polizisten jüngst zu einer Art Widerstand gegen die AfD aufrief, habe einen am Boden liegenden Mauerflüchtling mit Tritten misshandelt - er soll ihm außerdem eine Pistole in den Mund gedrückt haben.
Im Politunterricht rief er zur „Vernichtung“ von Mauerflüchtlingen auf und demütigte Soldaten, die daneben schossen.
Ein Zeitzeuge, der mit Gesicht, Klarnamen und eidesstattlicher Versicherung seine Erlebnisse wiedergibt, erhebt diese schweren Vorwürfe. Der DDR-Forscher Hubertus Knabe hält ihn für „sehr glaubwürdig“.
Sven Hübers Anwalt schrieb uns dazu einen 6-seitigen Brief und wies alle Vorwürfe zurück - nur merkwürdig, dass wir aus diesem Schreiben weder zitieren noch es „in anderer Weise publizistisch nutzen” dürfen.“
Das sind alles Bilder von gestern. Ich weiß nicht, wann ein Politiker zuletzt so vom Volk gefeiert wurde. Es herrscht eine fast revolutionäre Stimmung. An den Wahlständen der anderen Parteien sind selbst in den großen Städten nicht einmal ein Dutzend Menschen. Das bei den Landtagswahlen tatsächlich in eine absolute Mehrheit zu übersetzen bleibt schwierig. Aber ich denke, Siegmund wird massiv Nichtwähler mobilisieren, und davon hat die AfD bisher immer profitieren können.
(Aufrufe in der YouTube-Anzeige hängen immer bisschen nach)
Selbst als Nicht-AfDler sollte man anerkennen, was Siegmund für einen fulminanten Wahlkampf fährt. Besser kann man seine Ansichten kaum vermarkten. Von den anderen Parteien hört man derweilen gar nichts.
Gerade eben passiert. Pfefferspray, Tritte, und Werkzeuge wie Hammer kamen zum Einsatz.
Hoffentlich wird die linksradikale Regierung in MV im September endlich abgewählt.
At the Clinical Infectious Diseases Research Center of Department I of Internal Medicine at the University Hospital of Cologne, a patient with HIV infection was treated for the first time worldwide with the novel, broadly neutralizing antibody BNT351—as part of the international Phase I trial NCT07392372 (sponsor: BioNTech SE).
The University Hospital of Cologne is the only study center in Europe. Prof. Dr. Clara Lehmann (Department I of Internal Medicine) is the principal investigator at the site. “We view BNT351 as a promising candidate for the treatment and—as passive immunization—prevention of HIV infection. The treatment of the first patient marks an important step in translational HIV research at the Cologne site,” says Prof. Lehmann.
Weltweit erstmals HIV-Antikörper BNT351 eingesetzt– Start der Phase-I-S
Rückfälle bei Brustkrebs: Mini-Studie zeigt Erfolg von Impfung - SWR Aktuell
Breast cancer is the most common cancer among women in Germany. Many women now have good chances of recovery. However, there is still a very aggressive form of breast cancer that has so far been virtually incurable. This is triple-negative breast cancer.
Prof. Dr. Marcus Schmidt is conducting research on this topic at Mainz University Medical Center. He has now co-authored a paper in *Nature* presenting the results of a small study. “Nature” is a prestigious scientific journal.
Tailored Vaccine for Aggressive Breast Cancer
The research team’s idea: Vaccines are tailored individually for each patient. To this end, a patient’s tumor is first examined in detail. Then, a customized mRNA vaccine is developed.
For this study, the researchers focused exclusively on female patients with aggressive triple-negative breast cancer. Barbara Weiler is one of the study participants. She received this exact diagnosis in 2016. She subsequently underwent chemotherapy and radiation therapy. Many of these patients experience a relapse, and it was precisely for these cases that Dr. Schmidt, a physician in Mainz, sought a solution.
This initial study was small in scale; only 14 patients were able to participate. Barbara Weiler first received several doses of a standard vaccine before being administered the personalized vaccine eight times.
BioNTech Laid the Groundwork for mRNA Vaccines
The Mainz-based company BioNTech had already laid the groundwork for mRNA vaccines in general many years ago—this type of vaccine has become familiar to the general public during the COVID-19 pandemic.
BioNTech has since specialized in other types of cancer in its cancer research. However, Schmidt, a physician from Mainz, stayed the course and continued his research into immunotherapy to prevent relapses in triple-negative breast cancer. The study’s results confirm the approach, and the researcher was “rewarded” with the publication of his article in the prestigious journal *Nature*.
It is feasible, and the side effects are manageable. -Prof. Dr. Marcus Schmidt
Schmidt sums up his research: “Basically, we can see—and this was actually the goal of the study—that it is feasible. The side effects are very manageable, and we can trigger a strong immune response in nearly all patients.”
This assessment is shared by Prof. Dr. Annette Hasenburg, head of the Department of Women’s Health at Mainz University Medical Center: “We know that this approach works and that we can build on this, perhaps even for other types of cancer.” She adds that it is a promising new way to give hope to women with fairly aggressive breast cancer.
Large-Scale Study Needed in the Fight Against Breast Cancer
We don’t want to raise unrealistic hopes, says researcher Schmidt. Now we need to take the next step. That requires a randomized trial. In such a study, participants are randomly assigned to receive either the therapy being tested or a placebo or standard treatment. “Only then can we move toward approval, and only then can we say with a clear conscience, ‘Yes, this truly benefits patients,’” says Dr. Schmidt.
Money, Time, Ideas, and Bright Minds Needed
According to Hasenburg, a large-scale study like this requires money, ideas, BioNTech’s mRNA platform, bright minds, and time.
So there is still a long way to go before, in the best-case scenario, a treatment is available on the market for all patients. For Barbara Weiler, participating in the study was a stroke of luck. She has been symptom-free for eight years and is now considered cancer-free, as was confirmed at her most recent appointment at the Women’s Clinic in Mainz.
At the Clinical Infectious Diseases Research Center of Department I of Internal Medicine at the University Hospital of Cologne, a patient with HIV infection was treated for the first time worldwide with the novel, broadly neutralizing antibody BNT351—as part of the international Phase I trial NCT07392372 (sponsor: BioNTech SE).
The University Hospital of Cologne is the only study center in Europe. Prof. Dr. Clara Lehmann (Department I of Internal Medicine) is the principal investigator at the site. “We view BNT351 as a promising candidate for the treatment and—as passive immunization—prevention of HIV infection. The treatment of the first patient marks an important step in translational HIV research at the Cologne site,” says Prof. Lehmann.
$BNTX BioNtech
Insgesamt sollen im ersten Schritt 5500 Stellen aufgebaut werden. Imo sehr wichtig, gerade für den Süden.
BioNTech ($BNTX) is arguably the most undervalued stock in the biotech sector today. At its core, the company effectively combines the mRNA-knowledge of Moderna with Summit Therapeutics Ivonescimab. Yet, the market is pricing it as if neither of those assets exists.
The discrepancy becomes glaring when comparing enterprise values (EV):
| Company | Market Cap | Cash & Equivalents | Enterprise Value (EV) |
|---|---|---|---|
| Moderna ($MRNA) | $32 Billion | $6 Billion | $26 Billion |
| Summit Therapeutics ($SMMT) | $12 Billion | $0.5 Billion | $11.5 Billion |
| BioNTech ($BNTX) | $24 Billion | $20 Billion | $4 Billion |
A $4 billion EV is remarkably low for a company that still generates $500 million to $1 billion in annual cash flow from its profitable COVID-19 franchise and is unprofitable only because it spends over 2 billion USD on R&D every year. Furthermore, BioNTech recently bought its german competitor CureVac, securing the largest intellectual property portfolio in the mRNA space, and is currently running over 25 Phase 2 and Phase 3 clinical trials in oncology.
BioNTech's leadership has stated a clear goal: at least 10 approvals in different cancer indications by 2030. Given the depth of their pipeline, this target is entirely realistic. While they maintain several infectious disease candidates, oncology is the clear priority.
The most compelling candidate is BNT327, a PD-L1xVEGF-A bispecific antibody. In June 2025, Bristol Myers Squibb (BMS) agreed to pay BioNTech $3.5 billion for just 50% of Pumitamig, with BioNTech eligible for up to $7.6 billion in additional milestone payments.
This deal alone implies that the remaining 50% of Pumitamig is worth more than BioNTech's entire Enterprise Value.
Since the BMS partnership, BNT327 has rapidly expanded into 24 different indications, almost all of which are Phase 2 and Phase 3 trials. The most critical target is lung cancer, which accounts for the highest number of cancer deaths worldwide. Here is an excerpt from one of the recently published studies:
Clinical Efficacy (ROSETTA-Lung-02 Interim Analysis): Tested in 40 untreated patients with advanced Non-Small Cell Lung Cancer (NSCLC), Pumitamig plus chemotherapy delivered stunning results:
Historically, Pembrolizumab (Keytruda) plus chemotherapy in comparable first-line NSCLC populations yields ORRs of approximately 45–60%. BNT327 is demonstrating an above-average response signal and positioning itself to replace Keytruda as the new backbone of cancer therapy. With $31.6 billion in 2025, Keytruda is the highest-grossing drug of all time.
Of course, Merck isn't sitting idly by. The company is continuing to expand Keytruda as the foundation for "novel-novel combinations." These combinations are generally considered the future of cancer therapy, combining several cutting-edge medical treatments into one. However, BioNTech has a decisive advantage here. While Merck's Keytruda and Summit's Ivonescimab are advancing PD-1/VEGF inhibitors, BioNTech's Pumitamig relies specifically on PD-L1/VEGF inhibition. The small structural difference between PD-1 and PD-L1 means that BNT327 acts more directly on the tumor, possibly resulting in significantly lower toxicity.
Low toxicity is the ultimate prerequisite for successful combination therapies, particularly with antibody-drug conjugates (ADCs). BioNTech has spent years preparing for this future of combination therapies, in which it has a significant advantage: 10 Phase 2 "novel-novel" combination trials are currently underway.
Due to the novel-novel strategy, BioNTech is not solely focused on BNT327. Candidates like BNT323, an ADC used in these combination trials, have standalone blockbuster potential, defined as generating more than $1 billion in annual revenue.
Consider the Phase 3 trial of BNT323 (trastuzumab deruxtecan) for hormone receptor-positive (HR+) metastatic breast cancer with low HER2 expression. The primary completion date of this trial was recently postponed from May 30, 2026, to June 30, 2026. A delay in data collection often suggests that the drug is exceeding expectations, meaning patients are living longer without progression. The current standard of care for HER2-low breast cancer is Enhertu, which achieved a progression-free survival (PFS) of 10.1 months in 2022. BioNTech's study design was likely based on this length.
And that’s just one pipeline candidate in a single indication. As I’ve already mentioned, BioNTech’s pipeline consists of a total of 30 different drugs and 25+ Phase 2 and Phase 3 clinical trials in oncology alone. If I were to describe every single candidate in every indication, it would fill volumes. I just want to emphasize that the expectation of 10 approvals by 2030 - and thus revenue of at least 5–10 billion USD - is very realistic.
BNT323 for HR+ metastatic breast cancer
Primary Completion was in June 2026. Data cleaning and statistical analysis typically take 4 to 8 weeks. We can therefore expect topline data via a press release in late summer (August/September 2026). The detailed presentation is likely to take place at the European Society for Medical Oncology (ESMO) Congress in September or at the major breast cancer conference, the Society of American Breast Cancer Surgeons (SABCS), in December.
Importance: This would be BioNTech’s first-ever oncology product.
BNT122 for early-stage colorectal cancer (adjuvant)
Since completion is scheduled for November 2026, we will most likely not see actual clinical data until the first quarter of 2027 or, at the very latest, as a “late-breaking abstract” just before the end of 2026.
Importance: This would validate mRNA as a drug class and prevent Moderna from remaining the sole market leader.
BNT327 for stage 1 hepatocellular carcinoma (June 2026) & stage 1 colorectal cancer (August 2026); For hepatocellular carcinoma (June), we can expect data in early fall (Q3 2026). The colorectal cancer data (August) are likely to be released toward the end of the year (Q4 2026), possibly around the time of the SITC immuno-oncology conference in November.
Importance: The Phase 2 data for these two major gastrointestinal cancers will show whether the drug can be used broadly, not just for lung cancer.
BNT316 for platinum-resistant ovarian cancer
Since the date has been pushed back to November, the topline results will likely not be published until early 2027, unless BioNTech provides an update in advance in a quarterly report.
Importance: The postponement of the date from June to November 2026 - with patient recruitment already complete - strongly suggests that patients are living longer than originally calculated in the study protocol. Ovarian cancer is difficult to treat, and a survival benefit here would be a massive success for OncoC4 and BioNTech.
No bull thesis is complete without addressing the risks, though the market's current fears appear fundamentally misplaced:
TL;DR: BioNTech is absurdly undervalued, particularly when stacked against competitors like Moderna and Summit Therapeutics. Between an unvalued $20 billion cash pile, a catalyst-rich timeline over the next 12 months and a very likely steep revenue expansion over the next years it is difficult to see how this stock doesn't double or triple by 2030 with even a baseline of clinical luck.
Ohne Paywall:
„FRANKFURT—For decades, thousands of niche, world-class manufacturers that form the backbone of the German economy relied on an unassailable moat: unmatched quality. Now that moat is drying up.
The Mittelstand—a broad tier of midsize manufacturers, mainly specialized in capital and intermediate goods and reliant on exports—once thrived by making machines for factories everywhere. But China is now closing the quality gap and offering prices as low as half those of their European rivals.
As panic spreads among German manufacturers, layoffs are rolling through formerly prosperous towns and villages with no living memory of a downturn. The moment could become a political turning point for a country whose wealth was largely created by the Mittelstand, or “middle-class”—shorthand for the inner core of Europe’s largest economy.
For the first time in decades, Germany now imports more advanced capital goods from China than it exports there. Manufacturers are suddenly on the defensive, not just in China and elsewhere, but also at home. Many Mittelstand firms are idling workers, cutting jobs or shifting production, including to China.
Patric Burkhart, managing director of machinery manufacturer Aura, based in southwest Germany with 115 employees and around $30 million in annual revenue, said Chinese competition had surged over just the past six months, causing orders to dry up.
Aura makes heating equipment that is built into bigger industrial machines, such as presses, ovens and extruders—which make everything from plastic bags and window frames to car parts and snacks.
A Chinese competitor recently emerged in the market, creating strong price pressure, Burkhart said. To win projects with the incumbent German and Japanese manufacturers, he said, “I have to be very creative.”
German industry is losing more than 10,000 jobs every month, according to a May report by EY. Industrial output declined by around 10% between February 2022 and early 2026, with energy-intensive sectors plunging by more than 15%.
Germany’s trade balance with China in capital goods slid from a surplus of roughly 750 million euros to a €500 million deficit between mid-2024 and August 2025 on a 12-month rolling average, according to New York-based Apollo Global Management. Germany’s machine-tools exports to China slumped by around one-third in the first quarter from a year earlier.
If European policymakers don’t take tougher measures to protect industry, “you could see a very rapid decline of the German Mittelstand,” said Noah Barkin, senior adviser at the research firm Rhodium Group.
European leaders are seeking new legal powersto hit back at China. China’s overall goods exports to Germany alone have jumped 17% this year through May compared with the year prior, and those to the European Union have increased 16%, according to dollar-denominated data from Chinese customs.
China has increasingly leaned on manufacturing to drive economic growth following an epic property-market collapse. Facing weak demand at home and overflowing warehouses, factories are aggressively selling overseas, driving the nation’s trade surplus to a historic $1.2 trillion last year.
This evolution was a deliberate, state-backed engineering feat. Under its “10,000 Little Giants” initiative, the Chinese government funneled massive subsidies, tax breaks and state resources into thousands of specialized midsize firms, explicitly designed to replace Germany’s famed “hidden champions.”
There are still German companies that make products that China needs, said Barkin. These include Trumpf, a maker of lasers, and Zeiss, which manufactures optical devices used in medical machines and chip-making equipment. But Beijing is trying to address those dependencies and produce those goods.
When a manufacturer in Eastern Europe or South America sets up a new plant, they can now buy the entire ecosystem—the injection machines, robotic arms, dryers and cloud management software—directly from a single, unified Chinese vendor.
“China has already eaten much of German industry’s lunch and is preparing to start on dinner,” the Centre for European Reform, a London-based think tank, bluntly warned in a recent report.
Compounding the crisis are high energy prices and weak demand in Europe, deflationary pressures in China that lower export prices, and a yuan many economists believe is undervalued.
Competition is particularly fierce in sectors where scale matters, such as heat pumps or autos, said Clemens Fuest, president of the Ifo Institute for Economic Research, a think tank. More specialized firms are faring better for now. “It is hard to say where this will end,” Fuest said.
Mittelstand businesses, which long prided themselves on a die-hard free-trade ethic, have recently started requesting government protection from state-backed Chinese firms.
Chinese competitors already control one-third of global production in the machinery sector, said Oliver Richtberg, head of foreign trade at the Machinery and Equipment Manufacturers’ Association, or VDMA, a lobby group whose members employ one million German workers. The tipping point is fast approaching, Richtberg said: “If they get to 40% or 50%, we won’t have any levers left.”
The EU has launched a record number of trade cases against Beijing over the past two years, but those measures cover a fraction of total Chinese imports. Broader and tougher trade defenses discussed at a June summit meeting in Brussels will likely take a year or more to materialize.
Michael Suess, a longtime Siemens executive and now executive chairman of Swiss coatings manufacturer Oerlikon, said the German Mittelstand is in trouble mainly because of high costs at home and a new generation of family entrepreneurs he sees as lacking ambition.
“Yes, China is getting more competitive,” Suess said. But “Germany needs real reforms, we have to get out of our comfort zone.”
Still, over three-quarters of German mechanical engineering companies see competition from China as the biggest strategic challenge worldwide, according to a survey published in January by Hamburg-based consulting firm Infront.
Back at Aura, Burkhart said Chinese, Japanese and even German customers increasingly want him to manufacture in China. One motivation is cost. For Chinese manufacturers, there is also rising political pressure to transfer value creation to China.
Burkhart, who once produced exclusively in Germany, now makes 20% of his products in China. That share could increase to 70% if nothing changes in Europe, he said.
“We’re in a very sticky situation,” he said. “It is a historic change that brings the whole society under pressure.”
Moin,
ich habe 2025 als Werkstudent 20 Stunden pro Woche bis März gearbeitet und gleichzeitig bis Oktober studiert. Mein Erstwohnsitz ist das Haus meiner Eltern (hat sich während der Corona-Zeit so eingebürgert). Das war kein Fernstudium, sondern ein normales Präsenzstudium. Ich habe zwar eine Wohnung am Studienort, war aber fast immer zu Hause. Mein Studienort liegt 330 km von meinem Erstwohnsitz entfernt. Ich war fast nur für Klausuren und für Gespräche mit meinem Dozenten bezüglich meiner Bachelorarbeit (insg. 2025 10 Mal) dort. Meine Arbeitsstelle liegt 80 km von meinem Heimatort entfernt. Dort war ich etwa einmal pro Woche und habe die restlichen drei Tage im Homeoffice gearbeitet.
Kann ich sowohl die Werbungskosten für die Arbeit als auch die Sonderausgaben fürs Studium absetzen?
Die Beträge sind so hoch, dass ich Angst habe, das Finanzamt könnte Probleme machen.
Arbeit wäre ich bei:
Entfernungspauschale (Hin und Zurück): 8 x 80 x 2 x 0,3 = 384
Home-Office: 32 x 6 =192
Kontoführungsgebühr, Handyrechnung, Beiträge zu Berufsverbänden, Arbeitskleidung = 110 €
Also insgesamt 686€
Beim Studium wäre ich bei:
Entfernungspauschale (Erste Tätigkeitsstelle Einfache Strecke): (20 x 0,3 + 310 x 0,38) x 10= 1238 €
Semestergebühren 404 €
Lernpauschale Home-Office: 130 x 6 =780€
Also insgesamt 2.422 €
Zusammen 3108€.
Ist das realistisch oder habe ich irgendwo einen Fehler gemacht? Grundsätzlich habe ich neben meinem Gehalt Kapitalerträge, sodass sich das Absetzen lohnen würde.